Protein tyrosine phosphatase 2 (SHP-2) has long been proposed as a cancer drug target. Several small-molecule compounds with different mechanisms of SHP-2 inhibition have been reported, but none are commercially available. Pool selectivity over protein tyrosine phosphatase 1 (SHP-1) and a lack of cellular activity have hindered the development of selective SHP-2 inhibitors. In this review, we describe the binding modes of existing inhibitors and SHP-2 binding sites, summarize the characteristics of the sites involved in selectivity, and identify the suitable groups for interaction with the binding sites.

中文翻译：

---

酪氨酸磷酸酶SHP-2中的抑制剂结合位点。

长期以来，人们一直提出蛋白质酪氨酸磷酸酶2（SHP-2）作为抗癌药物的靶标。已经报道了几种具有不同的SHP-2抑制机制的小分子化合物，但是没有一种可商购。对蛋白质酪氨酸磷酸酶1（SHP-1）的池选择性和缺乏细胞活性阻碍了选择性SHP-2抑制剂的发展。在这篇综述中，我们描述了现有抑制剂和SHP-2结合位点的结合方式，总结了选择性所涉及位点的特征，并确定了与结合位点相互作用的合适基团。